Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Intensive Care Med. 2017 Nov;43(11):1602-1612. doi: 10.1007/s00134-017-4782-4. Epub 2017 May 2.
Guidelines recommend administering antibiotics within 1 h of sepsis recognition but this recommendation remains untested by randomized trials. This trial was set up to investigate whether survival is improved by reducing the time before initiation of antimicrobial therapy by means of a multifaceted intervention in compliance with guideline recommendations.
The MEDUSA study, a prospective multicenter cluster-randomized trial, was conducted from July 2011 to July 2013 in 40 German hospitals. Hospitals were randomly allocated to receive conventional continuous medical education (CME) measures (control group) or multifaceted interventions including local quality improvement teams, educational outreach, audit, feedback, and reminders. We included 4183 patients with severe sepsis or septic shock in an intention-to-treat analysis comparing the multifaceted intervention (n = 2596) with conventional CME (n = 1587). The primary outcome was 28-day mortality.
The 28-day mortality was 35.1% (883 of 2596 patients) in the intervention group and 26.7% (403 of 1587 patients; p = 0.01) in the control group. The intervention was not a risk factor for mortality, since this difference was present from the beginning of the study and remained unaffected by the intervention. Median time to antimicrobial therapy was 1.5 h (interquartile range 0.1-4.9 h) in the intervention group and 2.0 h (0.4-5.9 h; p = 0.41) in the control group. The risk of death increased by 2% per hour delay of antimicrobial therapy and 1% per hour delay of source control, independent of group assignment.
Delay in antimicrobial therapy and source control was associated with increased mortality but the multifaceted approach was unable to change time to antimicrobial therapy in this setting and did not affect survival.
指南建议在脓毒症识别后 1 小时内给予抗生素,但这一建议尚未通过随机试验得到验证。本试验旨在通过遵守指南建议的多方面干预措施来减少开始抗菌治疗前的时间,从而研究生存是否得到改善。
MEDUSA 研究是一项前瞻性多中心集群随机试验,于 2011 年 7 月至 2013 年 7 月在德国的 40 家医院进行。医院被随机分配接受常规连续医学教育(CME)措施(对照组)或包括当地质量改进团队、教育外展、审核、反馈和提醒在内的多方面干预措施。我们对 4183 名严重脓毒症或脓毒性休克患者进行了意向治疗分析,将多方面干预组(n=2596)与常规 CME 组(n=1587)进行了比较。主要结局是 28 天死亡率。
干预组 28 天死亡率为 35.1%(2596 例患者中的 883 例),对照组为 26.7%(1587 例患者中的 403 例;p=0.01)。干预并不是死亡的危险因素,因为这种差异从研究开始就存在,并且不受干预的影响。干预组抗菌治疗的中位时间为 1.5 小时(四分位距 0.1-4.9 小时),对照组为 2.0 小时(0.4-5.9 小时;p=0.41)。抗菌治疗每延迟 1 小时,死亡风险增加 2%,源控制每延迟 1 小时,死亡风险增加 1%,与分组无关。
抗菌治疗和源控制的延迟与死亡率的增加有关,但在这种情况下,多方面的方法无法改变抗菌治疗的时间,也没有影响生存。